Abstract: The invention concerns a sodium channel blocker for the treatment of a reduction or loss of superficial sensitivity or sense of touch of a human being or another mammal

Abstract: The invention concerns a sodium channel blocker for the treatment of a reduction or loss of superficial sensitivity or sense of touch of a human being or another mammal.

Abstract: The invention discloses a vector plasmid called “GFLV silencing construct” that confers resistance and sanitation against the grapevine fanleaf virus (GFLV); plant cells transformed with said vector plasmid and a method to impart resistance and sanitation against the grapevine fanleaf virus (GFLV) in non-transgenic grapevines when being grafted onto seedlings generated from cells transformed with said plasmid vector. The “GFLV silencing construct” plasmid vector of the invention comprises inverted sequence duplicates coding for the grapevine fanleaf virus (GFLV) capsid protein.

Abstract: The invention concerns a sodium channel blocker for the treatment of a reduction or loss of superficial sensitivity or sense of touch of a human being or another mammal.

Abstract: The present invention relates to a fish vaccine. More specifically the invention relates to a vaccine to protect salmon against infection by Piscirickettsia salmonis. The invention is based on or derived from the nucleic acid or amino acid sequence of antigens from Piscirickettsia salmonis. Nucleic acid and/or amino acid sequences may be used in the preparation of a vaccine to protect against infection by Piscirickettsia salmonis.

Abstract: Methods and compositions are provided for recombinant DNA production of Factor VIIIC and truncated derivatives thereof. Based on amino acid sequences, probes are developed for isolating messenger RNA, cDNA and/or chromosomal DNA encoding for Factor VIIIC. The Factor VIIIC gene in its entirety, a fragment thereof, or a cDNA is then used for expression of Factor VIIIC in a host. The bacteriophage ?FVIII23D containing the 14.43 kb EcoRI fragment was deposited at the A.T.C.C. on Jan. 4, 1984 and given Accession No. 40094. Also, the vector pSVF8-200 was deposited at the A.T.C.C. on Jul. 17, 1985 and given Accession No. 40190.

Abstract: The present invention relates to a fish vaccine. More specifically the invention relates to a vaccine to protect salmon against infection by Piscirickettsia salmonis. The invention is based on or derived from the nucleic acid or amino acid sequence of antigens from Piscirickettsia salmonis. Nucleic acid and/or amino acid sequences may be used in the preparation of a vaccine to protect against infection by Piscirickettsia salmonis.

Abstract: Novel methods, membrane supports and immunodiagnostic test kits for diagnosing Helicobacter pylori infection, are disclosed. The methods can also be used to monitor the progress of treatment of an infection. The methods, supports and kits employ both type-common and type-specific H. pylori antigens and can conveniently be performed in a single-step assay format. The methods provide for highly accurate results and discriminate between H. pylori Type I and H. pylori Type II infection so that an accurate diagnosis can be accomplished.

Abstract: The present invention relates to a fish vaccine. More specifically the invention relates to a vaccine to protect salmon against infection by Piscirickettsia salmonis. The invention is based on or derived from the nucleic acid or amino acid sequence of antigens from Piscirickettsia salmonis. Nucleic acid and/or amino acid sequences may be used in the preparation of a vaccine to protect against infection by Piscirickettsia salmonis.

Abstract: The present invention relates to a fish vaccine. More specifically the invention relates to a vaccine to protect salmon against infection by Piscirickettsia salmonis. The invention is based on or derived from the nucleic acid or amino acid sequence of antigens from Piscirickettsia salmonis. Nucleic acid and/or amino acid sequences may be used in the preparation of a vaccine to protect against infection by Piscirickettsia salmonis.

Abstract: Methods and compositions are provided for recombinant DNA production of Factor VIIIC and truncated derivatives thereof. Based on amino acid sequences, probes are developed for isolating messenger RNA and/or chromosomal DNA encoding for Factor VIIIC. The Factor VIIIC gene in its entirety or encoding for a fragment thereof is then used for expression of Factor VIIIC in a host. The bacteriophage .lambda.FVIII23D containing the 14.43 kb EcoRI fragment was deposited at the A.T.C.C. on Jan. 4, 1984 and given Accession No. 40094.

Abstract: Superoxide dismutase (SOD) analogs whose amino acid sequence includes a heterologous peptide domain such as the RGDX tetrapeptide found in fibronectin or the LGGAKQAGDV decapeptide found in fibrinogen that enables the analog to bind to a moiety that is normally present at sites of desired SOD therapy. The domain is incorporated into the SOD sequence in a manner in which it is available to interact with such moieties but does not destroy the enzymatic activity of the molecule. The inclusion of the domain enables the analog to more readily access the target tissue upon which it is to act and/or increase the corporeal half-life of the molecule.

Abstract: A DNA having a base sequence coding for human epidermal growth factor has been synthesized in blocks, and cloned. Novel recombinant DNA transfer vectors containing said cloned DNA have been constructed. The codon usage of the sequence reflects the codon bias of yeast. The DNA sequence is useful for the large scale synthesis of human epidermal growth factor in yeast cells or microorganisms transformed by said recombinant DNA transfer vectors.

Abstract: Methods and compositions are provided for recombinant DNA production of Factor VIIIC and truncated derivatives thereof. Based on amino acid sequences, probes are developed for isolating messenger RNA, cDNA and/or chromosomal DNA encoding for Factor VIIIC. The Factor VIIIC gene in its entirety, a fragment thereof, or a cDNA is then used for expression of Factor VIIIC in a host.The bacteriophage .lambda.FVIII23D containing the 14.43kb EcoRI fragment was deposited at the A.T.C.C. on Jan. 4, 1984 and given Accession No. 40094. Also, the vector pSVF8-200 was deposited at the A.T.C.C. on July 17, 1985 and given Accession No. 40190.

Abstract: Methods and compositions are provided for recombinant DNA production of Factor VIIIC and truncated derivatives therfeof. Based on amino acid sequences, probes are developed for isolating messenger RNA and/or chromosomal DNA encoding for Factor VIIIC. The Factor VIIIC gene in its entirety or encoding for a fragment thereof is then used for expression of Factor VIIIC in a host.The bacteriophage .lambda.FVIII23D containing the 14.43kb EcoRI fragment was deposited at the A.T.C.C. on Jan. 4, 1984 and given Accession No. 40094.

Abstract: Hybridomas producing monoclonal antibodies specific for polypeptide fragments derived from human Factor VIIIC are provided. Class I hybridomas produce monoclonal antibodies reactive with a 80/77 kd doublet fragment or with both the 80/77 kd doublet and a 240 kd polypeptide. Class III hybridomas produce monoclonal antibodies reactive with the 240 kd polypeptide as well as a 92.5 kd fragment and its precursors. Class III antibodies show additional reactivity with a 40 kd thrombin digestion product. The monoclonal antibodies are useful for the separation of Factor VIIIC and its constituent polypeptides, as well as for the immunoassay of Factor VIIIC in biological samples.